Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the effect of possible exposure to THROMBIN JMI® on activated partial thromboplastin time (aPTT) at 48 hours post surgery in subjects with likelihood of prior exposure to THROMBIN JMI® within the past 4 years.


Clinical Trial Description

This study is intended to observe the effects of possible repeat exposure to topical THROMBIN-JMI® on aPTT. Adult men and women who are scheduled to undergo qualified surgeries (defined as surgeries likely to require the use of an active topical hemostatic agent, but not likely to require transfusion of plasma), and who complete the informed consent process, and who meet all of the inclusion criteria and none of the exclusion criteria will be eligible for the study. As an observational study any decisions regarding the necessity for treatment to achieve hemostasis with this hemostatic product as an aid for perioperative hemostasis will be determined by the surgeon based upon the individual subject's condition.

Consequently, several assumptions and estimations are made in the design of the study. It is assumed that 20% of enrolled subjects will have pre-surgery bovine thrombin antibodies, and that 60% will receive THROMBIN JMI® during the study surgery, resulting in approximately 75 subjects in the primary study cohort and 195 subjects in the primary reference cohort. The primary endpoint of aPTT is chosen as prolongation beyond the normal reference range indicates either a factor deficiency or presence of an inhibitor. The latter is identified by either no correction or partial correction during mixing studies. At 48 hours post potential secondary exposure the secondary immune response should be sufficiently mounted as to see any impact of neutralizing antibodies on the aPTT.

After completion of the study surgeries, subjects will be categorized into cohorts based on whether their pre-surgery plasmas had or did not have anti-topical bovine thrombin antibodies and whether the subject received or did not receive THROMBIN JMI® intraoperatively. The primary study cohort will be subjects with anti-topical bovine thrombin antibodies pre-surgery, who received THROMBIN JMI® during the study surgery. The primary reference cohort will be those subjects with no anti-topical bovine thrombin antibodies pre-surgery and who did not receive THROMBIN JMI® during the study surgery. Antibody assessments will be not be performed until the end of the study for all subjects. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT00775398
Study type Observational
Source Pfizer
Contact
Status Completed
Phase N/A
Start date November 2008
Completion date November 2009

See also
  Status Clinical Trial Phase
Completed NCT02594345 - Effect of Exosomes Derived From Red Blood Cell Units on Platelet Function and Blood Coagulation N/A
Completed NCT01422304 - Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038) Phase 3
Completed NCT03535090 - Coagulation After Intravenous Methylprednisolone Administration
Completed NCT02385006 - Thromboelastography and Pancreas-kidney Transplantation N/A
Recruiting NCT02745054 - Safety of Oral Anticoagulants Registry
Completed NCT01635361 - Understanding and Appraising the New Medicine Service in England N/A
Completed NCT01195025 - Volume Kinetics for Starch Solution and Acetated Ringers N/A
Completed NCT05365542 - Anticoagulation in Chronic Hemodialysis Patients Versus Hemodialyzer Fiber Patency, Bleedings and Quality of Life
Completed NCT02321917 - Rheoparin-coated Tubing System for Minimized Extracorporeal Circulation (MECC) N/A
Completed NCT03203148 - Two Monitors for Measuring the Activated Clotting Time: A Comparison